Monopar presents Phase 2 data for ALXN1840 in Wilson disease at EASL 2026

Monopar Therapeutics

ALXN1840 (tiomolibdate choline) Phase 2 study results presented at EASL International Liver Congress 2026.
Study evaluated effect on liver pathology and clinical symptoms in Wilson disease patients.
No specific efficacy or safety figures provided in the 8-K text; presentation is an image exhibit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.